Prokaryotics Receives $2.3 Million SBIR Award Supporting Its Immune Potentiation Program

Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has been awarded its third Small Business Innovation Research (SBIR) grant valued at up to $2.3 million from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).


Fundingportal helps organizations like yours to get funded >